Статья

Advanced Treatment of Wastewater by Biological Ion-Exchange Resin for Dissolved Organic Carbon and Pharmaceutical Removal

Yunbao YanState Key Laboratory of Pollution Control and Resource Reuse, School of the Environment, Nanjing University, Nanjing 210023, ChinaSunyuan ZongState Key Laboratory of Pollution Control and Resource Reuse, School of the Environment, Nanjing University, Nanjing 210023, ChinaChendong ShuangState Key Laboratory of Pollution Control and Resource Reuse, School of the Environment, Nanjing University, Nanjing 210023, ChinaQing ZhouState Key Laboratory of Pollution Control and Resource Reuse, School of the Environment, Nanjing University, Nanjing 210023, ChinaRong JiState Key Laboratory of Pollution Control and Resource Reuse, School of the Environment, Nanjing University, Nanjing 210023, ChinaAimin LiState Key Laboratory of Pollution Control and Resource Reuse, School of the Environment, Nanjing University, Nanjing 210023, China

2024en

ABI

Аннотация

The biological ion exchange (BIEX) process has been proposed by utilizing a simultaneous biodegradation and ion exchange process for reducing the brine waste production from ion-exchange resin (IER) regeneration. In this work, we investigated two BIEX systems for biological effluent treatment, employing MAEX resin and Purolite A860 resin, which were compared with bioactivated carbon (BAC) and traditional activated sludge (AS). Over 0–120 days of operation, dissolved organic carbon (DOC) removal values were 52.5% (bio-MAEX), 48.1% (bio-A860), 18.5% (BAC), and 10.5% (AS). Both IERs could enhance biological activity, as indicated by their higher ATP and protein levels. Consequently, both BIEX systems were capable of a rapid restart within 15 days after storage at 4 °C, achieving stable DOC removal values of 45% (bio-MAEX) and 40% (bio-A860). As the ion exchange/adsorption reached equilibrium, the biocontribution to DOC removal for both BIEX systems increased from 35% (0–120 days) to 63.5% (121–240 days). Furthermore, the removal efficiencies for pharmaceuticals (ibuprofen, indomethacin, diclofenac, roxithromycin, and clarithromycin) were 92.7% (bio-MAEX), 90.9% (bio-A860), 89.5% (BAC), and 86.3% (AS). The biocontribution values to pharmaceutical removal were evaluated as 53.9 ± 6.4% (bio-MAEX), 47.5 ± 11.8% (bio-A860), and 38.9 ± 11.0% (BAC). The results showed that BIEX can perform well in the advanced treatment.

Перевод пока недоступен

Идентификаторы

DOI: 10.1021/acsestwater.3c00646

Цитирования и источники

Цитирований: 2Использованных источников: 0

Показатели — AkademScholar